Ready to Buy the Dip? This Biotech Stock Is a Smart Buy
Moderna (NASDAQ: MRNA) saw its shares jump in 2021 and 2022 on the back of strong sales of its COVID-19 vaccine Spikevax. Now that those sales are slumping, the biotech company's shares have fallen more than 27% this year.
For long-term-minded investors, this provides an opportunity to buy an up-and-coming company on the dip -- and at a price that is only eight times forward earnings.
Spikevax helped prove to the world the effectiveness of messenger RNA (mRNA) technology. The company advanced three COVID-19 vaccines from phase 1 to commercial status in a year. It has two other promising vaccine candidates -- mRNA-1345 for respiratory syncytial virus (RSV) and mRNA-1010 for the flu -- that have traveled from phase 1 to phase 3 in two years and could soon be approved by the Food and Drug Administration (FDA).
Source Fool.com
Moderna Inc. Aktie
Mit 21 Buy-Einschätzungen und nur 2 Sell-Einschätzungen ist Moderna Inc. einer der Lieblinge unserere Community.
Ein Kursziel von 129 € für Moderna Inc. könnte zu einer Steigerung von mehr als 50% gegenüber dem aktuellen Kurs von 78.79 € führen.
